Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02388906
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.

Key Dates

Start date
Mar 16, 2015
Status verified
Apr 2025
Primary completion
Nov 26, 2018
Completion
Oct 16, 2024

Study Design

Enrollment
906 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ipilimumab and Placebo matching Nivolumab
  • Experimental: Nivolumab and Placebo matching Ipilimumab

Primary Outcome Measure

Recurrence-free Survival (RFS) [ Time Frame: up to 36 months ]

Locations (35)

FacilityCityStateZIPSite coordinators
Local Institution - 0036Little RockArkansas72205-
Local Institution - 0117La JollaCalifornia92093-0698-
Local Institution - 0189Los AngelesCalifornia90025-
Local Institution - 0006San FranciscoCalifornia94143-
Local Institution - 0021San FranciscoCalifornia94109-
Local Institution - 0010AuroraColorado80045-
Local Institution - 0004Washington D.C.District of Columbia20007-
Local Institution - 0012JacksonvilleFlorida32207-
Local Institution - 0019Miami BeachFlorida33140-
Local Institution - 0030OrlandoFlorida32806-
Local Institution - 0032TampaFlorida33612-
Local Institution - 0016AtlantaGeorgia30322-
Local Institution - 0106ChicagoIllinois60637-
Local Institution - 0013BostonMassachusetts02215-
Local Institution - 0170BostonMassachusetts02215-
Local Institution - 0171BostonMassachusetts02215-
Local Institution - 0015Ann ArborMichigan48109-5869-
Local Institution - 0002RobbinsdaleMinnesota55407-
Local Institution - 0017St LouisMissouri63110-
Local Institution - 0123HackensackNew Jersey07601-
Local Institution - 0095New BrunswickNew Jersey08903-
Local Institution - 0024New YorkNew York10016-
Local Institution - 0033New YorkNew York10065-
Local Institution - 0003CharlotteNorth Carolina28204-
Local Institution - 0025DurhamNorth Carolina27710-
Local Institution - 0157ColumbusOhio43210-
Local Institution - 0029PortlandOregon97239-
Local Institution - 0031PortlandOregon97213-
Local Institution - 0022AllentownPennsylvania18103-
Local Institution - 0001BethlehemPennsylvania18015-
Local Institution - 0026CharlestonSouth Carolina29425-
Local Institution - 0014NashvilleTennessee37203-1624-
Local Institution - 0005DallasTexas75246-
Local Institution - 0027CharlottesvilleVirginia22908-
Local Institution - 0126SeattleWashington98109-

Find similar trials in Little Rock, AR

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
Local Institution - 0036· Little Rock, ARLocal Institution - 0117· La Jolla, CALocal Institution - 0189· Los Angeles, CALocal Institution - 0006· San Francisco, CALocal Institution - 0021· San Francisco, CALocal Institution - 0010· Aurora, CO

Related Studies